{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T16:31:10Z","timestamp":1771000270377,"version":"3.50.1"},"reference-count":36,"publisher":"Royal College of Psychiatrists","issue":"4","license":[{"start":{"date-parts":[[2018,1,29]],"date-time":"2018-01-29T00:00:00Z","timestamp":1517184000000},"content-version":"unspecified","delay-in-days":12539,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Psychiatry"],"published-print":{"date-parts":[[1983,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Eighteen agoraphobic patients were randomly assigned to 12 week treatment with imipramine (I) or imipramine and programmed <jats:italic>in-vivo<\/jats:italic> exposure practice (l+BT) to investigate the contribution of behavioural instructions to the clinical effects of pharmacotherapy. Significantly greater improvement on phobic measures was found in the l+BT group compared to the I group. Differences were less marked on measures of panic and anxiety. The results suggest that imipramine possesses an antiphobic effect which can be substantially enhanced with programmed practice. Controlled large-scale investigations of the pharmacological and instructional effects of the pharmacotherapy of agoraphobia are needed for a definitive evaluation of the specific antiphobic effect of antidepressant drugs.<\/jats:p>","DOI":"10.1192\/bjp.143.4.348","type":"journal-article","created":{"date-parts":[[2008,8,12]],"date-time":"2008-08-12T19:20:52Z","timestamp":1218568852000},"page":"348-355","source":"Crossref","is-referenced-by-count":84,"title":["Pharmacological Treatment of Agoraphobia"],"prefix":"10.1192","volume":"143","author":[{"given":"Matig","family":"Mavissakalian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry","family":"Michelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert S.","family":"Dealy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"170","published-online":{"date-parts":[[2018,1,29]]},"reference":[{"key":"S0007125000200482_ref26","first-page":"91","article-title":"Agoraphobia: Behavioral and pharmacological treatments, preliminary outcome, and process findings","volume":"18","author":"Mavissakalian","year":"1982","journal-title":"Psychopharmacology Bulletin"},{"key":"S0007125000200482_ref24","doi-asserted-by":"crossref","unstructured":"Mavissakalian M. (1983) Antidepressants in the treatment of agoraphobia and obsessive-compulsive disorder. Comprehensive Psychiatry, (in press).","DOI":"10.1016\/0010-440X(83)90080-9"},{"key":"S0007125000200482_ref16","volume-title":"Fears and Phobias.","author":"Marks","year":"1969"},{"key":"S0007125000200482_ref2","volume-title":"Anxiety: New Research and Changing Concepts","author":"Appleby","year":"1981"},{"key":"S0007125000200482_ref36","doi-asserted-by":"publisher","DOI":"10.1016\/S0033-3182(71)71479-0"},{"key":"S0007125000200482_ref34","doi-asserted-by":"publisher","DOI":"10.1016\/S0005-7894(71)80062-X"},{"key":"S0007125000200482_ref21","volume-title":"Agoraphobia: Nature and Treatment.","author":"Mathews","year":"1981"},{"key":"S0007125000200482_ref14","volume-title":"Research in Neurosis","author":"Lader","year":"1978"},{"key":"S0007125000200482_ref12","volume-title":"Anxiety: New Research and Changing Concepts","author":"Klein","year":"1981"},{"key":"S0007125000200482_ref7","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.133.4.314"},{"key":"S0007125000200482_ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0005-7894(80)80031-1"},{"key":"S0007125000200482_ref18","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.111.476.561"},{"key":"S0007125000200482_ref28","unstructured":"Mavissakalian M. & Michelson L. (1983b) (Submitted for publication). Agoraphobia: Behavioral and pharmacological treatment."},{"key":"S0007125000200482_ref13","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1983.01790020033003"},{"key":"S0007125000200482_ref29","doi-asserted-by":"publisher","DOI":"10.1016\/0005-7967(79)90055-X"},{"key":"S0007125000200482_ref32","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.114.511.673"},{"key":"S0007125000200482_ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S0005-7894(78)80053-7"},{"key":"S0007125000200482_ref20","doi-asserted-by":"publisher","DOI":"10.1016\/0005-7967(79)90041-X"},{"key":"S0007125000200482_ref17","unstructured":"Marks I. M. (1981) Are there anticompulsive or antibiotic drugs? Review of the evidence. Paper presented to ACNP, San Diego, December."},{"key":"S0007125000200482_ref31","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1980.01780140053006"},{"key":"S0007125000200482_ref27","article-title":"Agoraphobia: Behavioral and pharmacological treatment. N = 49","volume":"19","author":"Mavissakalian","year":"1983a","journal-title":"Psychopharmacology Bulletin"},{"key":"S0007125000200482_ref11","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.119.549.129"},{"key":"S0007125000200482_ref23","article-title":"Pharmacologic treatment of anxiety disorders","volume":"43","author":"Mavissakalian","year":"1982","journal-title":"Journal of Clinical Psychiatry"},{"key":"S0007125000200482_ref1","unstructured":"American Psychiatric Association (1980) Diagnostic and Statistical Manual of Mental Disorders (DSM-III) (3rd ed.). Washington, DC."},{"key":"S0007125000200482_ref10","doi-asserted-by":"publisher","DOI":"10.1016\/0272-7358(82)90017-4"},{"key":"S0007125000200482_ref35","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1983.01790020019002"},{"key":"S0007125000200482_ref22","doi-asserted-by":"publisher","DOI":"10.1016\/S0005-7894(77)80161-5"},{"key":"S0007125000200482_ref19","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1983.01790020047004"},{"key":"S0007125000200482_ref33","article-title":"Phenelzine and exposure in the treatment of phobias","volume":"3","author":"Solyom","year":"1981","journal-title":"Biological Psychiatry"},{"key":"S0007125000200482_ref3","doi-asserted-by":"publisher","DOI":"10.1037\/0033-295X.84.2.191"},{"key":"S0007125000200482_ref8","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.23.1.56"},{"key":"S0007125000200482_ref25","volume-title":"Phobia: Psychological and Pharmacological Treatment.","author":"Mavissakalian","year":"1981"},{"key":"S0007125000200482_ref15","volume-title":"Agoraphobia: Multiple Perspectives on Theory and Treatment","author":"Liebowitz","year":"1982"},{"key":"S0007125000200482_ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S0005-7894(80)80047-5"},{"key":"S0007125000200482_ref4","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1961.01710120031004"},{"key":"S0007125000200482_ref30","volume-title":"Anxiety: New Research and Changing Concepts","author":"McNair","year":"1981"}],"container-title":["British Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0007125000200482","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T18:31:56Z","timestamp":1558636316000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0007125000200482\/type\/journal_article"}},"subtitle":["Imipramine versus Imipramine with Programmed Practice"],"short-title":[],"issued":{"date-parts":[[1983,10]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1983,10]]}},"alternative-id":["S0007125000200482"],"URL":"https:\/\/doi.org\/10.1192\/bjp.143.4.348","relation":{},"ISSN":["0007-1250","1472-1465"],"issn-type":[{"value":"0007-1250","type":"print"},{"value":"1472-1465","type":"electronic"}],"subject":[],"published":{"date-parts":[[1983,10]]}}}